Related Experiment Videos
Transfusion-dependent congenital dyserythropoietic anemia type I successfully treated with allogeneic stem cell
M Ayas1, A al-Jefri, A Baothman
1Department of Pediatric Hematology Oncology, King Faisal Specialist Hospital and Research Center (KFSH&RC), MBC 53, PO Box 3354, Riyadh 11211, Saudi Arabia.
Insights
Allogeneic stem cell transplantation (SCT) offers a new treatment for severe congenital dyserythropoietic anemia (CDA) type I. Three children achieved transfusion independence after SCT, marking a significant advancement in managing this rare anemia.
Area of Science:
- Hematology
- Pediatric Hematology
- Stem Cell Transplantation
Background:
- Severe congenital dyserythropoietic anemia (CDA) type I historically had limited treatment options.
- Therapies were primarily supportive, including blood transfusions and iron chelation.
Purpose of the Study:
- To evaluate the efficacy and safety of allogeneic stem cell transplantation (SCT) for transfusion-dependent CDA type I.
- To report the outcomes of SCT in pediatric patients with CDA type I.
Main Methods:
- Allogeneic stem cell transplantation (SCT) was performed in three children with CDA type I.
- Conditioning regimen included cyclophosphamide, busulphan, and antithymocyte globulin (ATG).
- Matched sibling donors were utilized for SCT.
Main Results:
- All three patients engrafted successfully post-SCT.
- All patients are alive and have achieved transfusion independence.
- This represents the first reported successful SCT for CDA type I.
Conclusions:
- Allogeneic stem cell transplantation (SCT) is a viable and effective treatment for severe congenital dyserythropoietic anemia (CDA) type I.
- SCT offers a potentially curative option, leading to transfusion independence in affected children.
- Further research may explore SCT for other types of CDA.
Abstract:
Until recently, therapy for patients with severe congenital dyserythropoietic anemia (CDA) has been limited to blood transfusions and chelation therapy. Three children with transfusion-dependent CDA type I underwent allogeneic stem cell transplantation (SCT) from matched sibling donors. Conditioning was with cyclophosphamide 50 mg/kg/day for 4 days, busulphan 4 mg/kg/day for 4 days, and antithymocyte globulin (ATG) 30 mg/kg for four doses pre-SCT. All patients engrafted and are alive, and transfusion independent. To our knowledge, this is the first report of successful SCT in the management of CDA type I.